Stay updated on GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page.

Latest updates to the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for a study of extended-release exenatide and albuminuria in people with type 2 diabetes is displayed, with study details, participation criteria, outcomes, and a study protocol document.SummaryDifference47%

- Check17 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide banner announces an NIH website transition and links to updates and FAQs, noting a change in terminology from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now renders a 403 Forbidden error instead of the study record content, with a header and navigation visible. This indicates an access restriction rather than data updates for the study.SummaryDifference18%

Stay in the know with updates to GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GLP-1 Agonist and Albuminuria in Type 2 Diabetes Clinical Trial page.